Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Overview

Journal Cancer Invest

Specialty Oncology

Date 2011 Apr 8

PMID 21469981

Citations 42

Authors

Susanna V Ulahannan

Julie R Brahmer

Affiliations

Soon will be listed here.

Abstract

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.

Citing Articles

Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.

Yu L, Liang X, Wang J, Ding G, Tang J, Xue J Genet Res (Camb). 2023; 2023:6782732.

PMID: 36688087 PMC: 9831708. DOI: 10.1155/2023/6782732.

Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.

Choudhary S, Doshi A, Luckett-Chastain L, Ihnat M, Hamel E, Mooberry S Bioorg Med Chem. 2021; 35:116061.

PMID: 33647840 PMC: 7995636. DOI: 10.1016/j.bmc.2021.116061.

Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.

Wu Q, Zhang B, Sun Y, Xu R, Hu X, Ren S Onco Targets Ther. 2019; 12:3545-3563.

PMID: 31190860 PMC: 6526173. DOI: 10.2147/OTT.S198621.

VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.

Liu L, Zhang Y, Wei J, Chen Z, Yu J J Cancer. 2019; 10(4):799-809.

PMID: 30854085 PMC: 6400799. DOI: 10.7150/jca.29643.

The expression level and prognostic value of HIPK3 among non-small-cell lung cancer patients in China.

Liu Y, Qian L, Yang J, Huang H, Feng J, Li X Onco Targets Ther. 2018; 11:7459-7469.

PMID: 30498360 PMC: 6207246. DOI: 10.2147/OTT.S166878.

References

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D . Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111(9):1287-95. PMC: 154450. DOI: 10.1172/JCI17929. View

Hurwitz H, Douglas P, Middleton J, Sledge G, Johnson D, Reardon D . Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013; 18(3):273-80. PMC: 3607523. DOI: 10.1634/theoncologist.2012-0339. View

Heist R, Fidias P, Huberman M, Ardman B, Sequist L, Temel J . A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3(10):1153-8. DOI: 10.1097/JTO.0b013e318187273f. View

Hanna N, Shepherd F, Fossella F, Pereira J, de Marinis F, von Pawel J . Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22(9):1589-97. DOI: 10.1200/JCO.2004.08.163. View

Socinski M . The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol. 2008; 3(6 Suppl 2):S119-23. DOI: 10.1097/JTO.0b013e318174e9be. View

Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E . Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3(5):511-5. DOI: 10.1097/JTO.0b013e31816de28f. View

Bremnes R, Camps C, Sirera R . Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2005; 51(2):143-58. DOI: 10.1016/j.lungcan.2005.09.005. View

Laurie S, Gauthier I, Arnold A, Shepherd F, Ellis P, Chen E . Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer.... J Clin Oncol. 2008; 26(11):1871-8. DOI: 10.1200/JCO.2007.14.4741. View

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

10.

Herbst R, Sun Y, Eberhardt W, Germonpre P, Saijo N, Zhou C . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010; 11(7):619-26. PMC: 3225192. DOI: 10.1016/S1470-2045(10)70132-7. View

11.

Jenab-Wolcott J, Giantonio B . Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009; 9(4):507-17. DOI: 10.1517/14712590902817817. View

12.

Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H . Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009; 64(6):1165-72. DOI: 10.1007/s00280-009-0979-8. View

13.

Clement-Duchene C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A . A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010; 5(11):1821-5. PMC: 4241413. DOI: 10.1097/JTO.0b013e3181f1d23c. View

14.

Dowlati A, Gray R, Sandler A, Schiller J, Johnson D . Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008; 14(5):1407-12. DOI: 10.1158/1078-0432.CCR-07-1154. View

15.

Kozloff M, Martin L, Krzakowski M, Samuel T, Rado T, Arriola E . Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012; 107(8):1277-85. PMC: 3494447. DOI: 10.1038/bjc.2012.406. View

16.

Cohen M, Gootenberg J, Keegan P, Pazdur R . FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007; 12(6):713-8. DOI: 10.1634/theoncologist.12-6-713. View

17.

Ramalingam S, Dahlberg S, Langer C, Gray R, Belani C, Brahmer J . Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008; 26(1):60-5. DOI: 10.1200/JCO.2007.13.1144. View

18.

Goss G, Arnold A, Shepherd F, Dediu M, Ciuleanu T, Fenton D . Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2009; 28(1):49-55. DOI: 10.1200/JCO.2009.22.9427. View

19.

Schiller J, Larson T, Ou S, Limentani S, Sandler A, Vokes E . Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009; 27(23):3836-41. DOI: 10.1200/JCO.2008.20.8355. View

20.

Sandler A, Schiller J, Gray R, Dimery I, Brahmer J, Samant M . Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol. 2009; 27(9):1405-12. PMC: 3527732. DOI: 10.1200/JCO.2008.16.2412. View